| Kent Dee Roundy, MD | |
|
1300 E Center St, Provo, UT 84606 | |
| (801) 344-4400 | |
| Not Available |
| Full Name | Kent Dee Roundy |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 19 Years |
| Location | 1300 E Center St, Provo, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619932175 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 5852286-1205 (Utah) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| State Of Utah | 6800797333 | 10 |
News Archive
A University of Alberta researcher and Canada Excellence Research Chair in Virology has made the discovery of a vaccine that will potentially help combat hepatitis C. Michael Houghton, who led the team that discovered the hepatitis C virus in 1989, announced his findings at the Canada Excellence Research Chairs Summit in Vancouver this afternoon. Currently, there are no vaccines against the disease available.
Nearly as many women who received only one embryo at a time gave birth as women who received two embryos. At the same time the risk of giving birth to twins is minimized. These are the findings of a major study from the Sahlgrenska Academy, at Göteborg University in Sweden.
A single session of a gene therapy developed by the Universitat Autònoma de Barcelona (UAB) cures Sanfilippo Syndrome A in animal models. This syndrome is a neurodegenerative disease that affects between 1 and 9 out of every 100,000 children, and causes the death of the child on reaching adolescence.
GeoVax Labs, Inc., an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, announced today that it has entered into definitive agreements with certain institutional investors, pursuant to which the Company has agreed to sell shares of its Series A convertible preferred stock at an aggregate purchase price of approximately $2.2 million and Series A warrants to purchase up to an aggregate of 2,933,333 shares of GeoVax common stock with an exercise price of $1.00 per share and a term of five years.
TearLab Corporation announced today that it is in receipt of a communication from the U.S. Food and Drug Administration indicating that the data submitted by the Company was not sufficient to gain approval of its CLIA Waiver categorization application for the TearLab Osmolarity System.
› Verified 5 days ago
| Entity Name | State Of Utah |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811978620 PECOS PAC ID: 6800797333 Enrollment ID: O20040117000195 |
News Archive
A University of Alberta researcher and Canada Excellence Research Chair in Virology has made the discovery of a vaccine that will potentially help combat hepatitis C. Michael Houghton, who led the team that discovered the hepatitis C virus in 1989, announced his findings at the Canada Excellence Research Chairs Summit in Vancouver this afternoon. Currently, there are no vaccines against the disease available.
Nearly as many women who received only one embryo at a time gave birth as women who received two embryos. At the same time the risk of giving birth to twins is minimized. These are the findings of a major study from the Sahlgrenska Academy, at Göteborg University in Sweden.
A single session of a gene therapy developed by the Universitat Autònoma de Barcelona (UAB) cures Sanfilippo Syndrome A in animal models. This syndrome is a neurodegenerative disease that affects between 1 and 9 out of every 100,000 children, and causes the death of the child on reaching adolescence.
GeoVax Labs, Inc., an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, announced today that it has entered into definitive agreements with certain institutional investors, pursuant to which the Company has agreed to sell shares of its Series A convertible preferred stock at an aggregate purchase price of approximately $2.2 million and Series A warrants to purchase up to an aggregate of 2,933,333 shares of GeoVax common stock with an exercise price of $1.00 per share and a term of five years.
TearLab Corporation announced today that it is in receipt of a communication from the U.S. Food and Drug Administration indicating that the data submitted by the Company was not sufficient to gain approval of its CLIA Waiver categorization application for the TearLab Osmolarity System.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kent Dee Roundy, MD Po Box 270, Provo, UT 84603-0270 Ph: (801) 344-4400 | Kent Dee Roundy, MD 1300 E Center St, Provo, UT 84606 Ph: (801) 344-4400 |
News Archive
A University of Alberta researcher and Canada Excellence Research Chair in Virology has made the discovery of a vaccine that will potentially help combat hepatitis C. Michael Houghton, who led the team that discovered the hepatitis C virus in 1989, announced his findings at the Canada Excellence Research Chairs Summit in Vancouver this afternoon. Currently, there are no vaccines against the disease available.
Nearly as many women who received only one embryo at a time gave birth as women who received two embryos. At the same time the risk of giving birth to twins is minimized. These are the findings of a major study from the Sahlgrenska Academy, at Göteborg University in Sweden.
A single session of a gene therapy developed by the Universitat Autònoma de Barcelona (UAB) cures Sanfilippo Syndrome A in animal models. This syndrome is a neurodegenerative disease that affects between 1 and 9 out of every 100,000 children, and causes the death of the child on reaching adolescence.
GeoVax Labs, Inc., an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, announced today that it has entered into definitive agreements with certain institutional investors, pursuant to which the Company has agreed to sell shares of its Series A convertible preferred stock at an aggregate purchase price of approximately $2.2 million and Series A warrants to purchase up to an aggregate of 2,933,333 shares of GeoVax common stock with an exercise price of $1.00 per share and a term of five years.
TearLab Corporation announced today that it is in receipt of a communication from the U.S. Food and Drug Administration indicating that the data submitted by the Company was not sufficient to gain approval of its CLIA Waiver categorization application for the TearLab Osmolarity System.
› Verified 5 days ago
Edward Leslie Kelly, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1300 E Center St, Provo, UT 84606 Phone: 801-344-4400 Fax: 801-344-4225 | |
Brent L Griffin, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1034 N 500 W, Provo, UT 84604 Phone: 801-357-4542 | |
Aaron William Sanders, DO Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 395 W Cougar Blvd Ste 601, Provo, UT 84604 Phone: 801-357-7525 | |
Sam J Coates, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1034 N 500 W, Provo, UT 84604 Phone: 801-357-4542 | |
Dr. Rodney A Cheal, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1300 E Center St, Provo, UT 84606 Phone: 801-344-4400 | |
Ms. Madhumathy Gundlapalli, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1300 E Center St, Provo, UT 84606 Phone: 801-344-4400 | |
Dr. Stephen Peters, PSYD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1157 N 300 W, Provo, UT 84604 Phone: 801-357-1200 |